Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 1;9(12):1461–1471. doi: 10.1242/dmm.026369

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 1. — In vivo characterization of the synergistic effect of lurbinectedin (PM01183) combined with gemcitabine. Nude athymic mice bearing subcutaneous tumors (SW-1990 or MIA PaCa-2) sized ca. 150 mm³ were randomly allocated and treated with PM01183 (0.180 mg kg⁻¹), gemcitabine (180.0 mg kg⁻¹) or its combination [PM01183 plus gemcitabine (0.180 mg kg⁻¹+180.0 mg kg⁻¹)]. (A,B) Tumor growth (median) curves for mice bearing SW-1190 (A) or MIA PaCa-2 (B) tumors and treated with the highest doses of PM01183, gemcitabine or its combination. (C,D) Antitumor activity of each single or combined high-dosed treatment followed by T/C values, defined as the change in tumor volume for each treated (T) and placebo (C) group during the placebo-treated survival period for mice bearing SW-1190 (C) or MIA PaCa-2 (D). (E,F) Determination of tumor fraction affected (F_a) by treatments, calculated according to the formula F_a=1– T/C and combination index (CI) determined by the CI-isobol method for mice bearing SW-1190 (E) or MIA PaCa-2 (F). Statistically significant differences at P<0.01 (two-tailed Mann–Whitney U-test).